Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
IPO Year: 2020
Exchange: NASDAQ
Website: silverbacktx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2022 | $25.00 → $3.50 | Buy → Neutral | Goldman |
| 4/1/2022 | $25.00 → $1.80 | Outperform → Mkt Perform | SVB Leerink |
| 4/1/2022 | $32.00 → $6.00 | Buy → Hold | Stifel |
| 4/1/2022 | Buy → Neutral | H.C. Wainwright | |
| 11/12/2021 | $42.00 → $25.00 | Outperform | SVB Leerink |
| 8/16/2021 | $46.00 → $49.00 | Outperform | SVB Leerink |
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously
SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously
Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously
H.C. Wainwright downgraded Silverback Therapeutics from Buy to Neutral
SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $25.00 from $42.00 previously
SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $49.00 from $46.00 previously
JonesTrading initiated coverage of Silverback Therapeutics with a rating of Buy and set a new price target of $50.00
SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $46.00 from $49.00 previously
SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $49.00 from $40.00 previously
Stifel reiterated coverage of Silverback Therapeutics with a rating of Buy and set a new price target of $60.00 from $58.00 previously